RTP Mobile Logo

Efficacy/tolerability of 2nd-line aflibercept vs bev beyond PD

Efficacy/tolerability of 2nd-line aflibercept vs bev beyond PD

How would you compare the efficacy of aflibercept to the use of bevacizumab on disease progression in the second-line setting?

How would you compare the side effects and tolerabilty of aflibercept to the use of bevacizumab on disease progression in the second-line setting?

60 yo with obvious progression within a few months of FOLFOX/bev?

60 yo with obvious progression within a few months of FOLFOX/bev?

What systemic treatment would you most likely recommend for the following patients:

A 60-year-old patient with asymptomatic mCRC receives FOLFOX/bevacizumab but within a few months experiences obvious disease progression. The tumor is KRAS wild type.

Same as above, but the tumor is KRAS mutant?

75 yo with slow progression 1 y after FOLFOX/bev -> 5-FU/bev?

75 yo with slow progression 1 y after FOLFOX/bev -> 5-FU/bev?

What systemic treatment would you most likely recommend for the following patients:

60 yo with slow progression 1 y after FOLFOX/bev -> 5-FU/bev?

60 yo with slow progression 1 y after FOLFOX/bev -> 5-FU/bev?

What systemic treatment would you most likely recommend for the following patients:

Consensus or Controversy, Issue 2: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Management of Colorectal Cancer in the Second-Line Setting

COCCRC13/2

TARGET AUDIENCE
This activity is intended for medical oncologists, hematologist-oncologists, hematology-oncology fellows, oncology nurses, radiation oncologists, colorectal-general surgeons and other healthcare practitioners involved in the management of colorectal cancer.

OVERVIEW OF ACTIVITY

5MJCHEM2013/2/

OVERVIEW OF ACTIVITY

RS for 40 yo, 1.5-cm node+ (1 node) ER+ IDC? No. of MammaPrint® (70-gene signature) assays ordered in past 1 y?

RS for 40-year-old, 1.5-cm node+ (1 node) ER+ IDC? No. of MammaPrint® (70-gene signature) assays ordered in past 1 y?

Would you order an Oncotype DX assay for a 40-year-old premenopausal woman with a 1.5-cm, ER-positive, HER2-negative IDC and 1 positive node?

Approximately how many MammaPrint® assays have you ordered in the past year?

RS for 40 yo, 0.8-cm node-neg ER+ IDC? A pt w/ 3.0-cm tumor?

RS for 40-year-old, 0.8-cm node-neg ER+ IDC? A pt w/ 3.0-cm tumor?

Would you order an Oncotype DX assay for a 40 yo premenopausal woman with a 0.8-cm, node-negative, ER-positive, HER2-negative IDC?

Would you order an Oncotype DX assay for a 40 yo premenopausal woman with a 3.0-cm, node-negative, ER-positive, HER2-negative IDC?

RS for 70 yo, 1.5-cm node-neg ER+ IDC? After 5 y continue/stop adj anastrozole?

RS for 70-year-old, 1.5-cm node-neg ER+ IDC? After 5 y continue/stop adj anastrozole?

Would you order an Oncotype DX assay for a 70-year-old postmenopausal woman with a 1.5-cm, node-negative, ER-positive, HER2-negative IDC?

Would you likely recommend that a 70-year-old postmenopausal woman with a 1.5-cm, node-negative IDC who received adjuvant TC and recently completed 5 years of anastrozole without problems continue or stop anastrozole therapy?

Oncotype DX® Recurrence Score® (RS) for 40 yo, 1.5-cm node-neg ER+ IDC? After 5 y continue/stop adj tamoxifen?

Oncotype DX® Recurrence Score® (RS) for 40-year-old, 1.5-cm node-neg ER+ IDC? After 5 y continue/stop adj tamoxifen?

Would you likely order an Oncotype DX® assay for a 40-year-old premenopausal woman with a 1.5-cm, node-negative, ER-positive, HER2-negative IDC?

RS for 40 yo, 1.5-cm node+ (1 node) ER+ IDC? No. of MammaPrint® (70-gene signature) assays ordered in past 1 y?

RS for 40-year-old, 1.5-cm node+ (1 node) ER+ IDC? No. of MammaPrint® (70-gene signature) assays ordered in past 1 y?

Would you order an Oncotype DX assay for a 40-year-old premenopausal woman with a 1.5-cm, ER-positive, HER2-negative IDC and 1 positive node?

Approximately how many MammaPrint® assays have you ordered in the past year?

RS for 40 yo, 0.8-cm node-neg ER+ IDC? A pt w/ 3.0-cm tumor?

RS for 40-year-old, 0.8-cm node-neg ER+ IDC? A pt w/ 3.0-cm tumor?

Would you order an Oncotype DX assay for a 40 yo premenopausal woman with a 0.8-cm, node-negative, ER-positive, HER2-negative IDC?

Would you order an Oncotype DX assay for a 40 yo premenopausal woman with a 3.0-cm, node-negative, ER-positive, HER2-negative IDC?

RS for 70 yo, 1.5-cm node-neg ER+ IDC? After 5 y continue/stop adj anastrozole?

RS for 70-year-old, 1.5-cm node-neg ER+ IDC? After 5 y continue/stop adj anastrozole?

Would you order an Oncotype DX assay for a 70-year-old postmenopausal woman with a 1.5-cm, node-negative, ER-positive, HER2-negative IDC?

Would you likely recommend that a 70-year-old postmenopausal woman with a 1.5-cm, node-negative IDC who received adjuvant TC and recently completed 5 years of anastrozole without problems continue or stop anastrozole therapy?

Oncotype DX® Recurrence Score® (RS) for 40 yo, 1.5-cm node-neg ER+ IDC? After 5 y continue/stop adj tamoxifen?

Oncotype DX® Recurrence Score® (RS) for 40-year-old, 1.5-cm node-neg ER+ IDC? After 5 y continue/stop adj tamoxifen?

Would you likely order an Oncotype DX® assay for a 40-year-old premenopausal woman with a 1.5-cm, node-negative, ER-positive, HER2-negative IDC?